^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia

Published date:
02/02/2021
Excerpt:
Susceptibility of patient samples for PTC596 in combination with S63845 or trametinib was significant for the majority of adverse risk primary and secondary AML with minimal efficacy in favorable risk AML, and correlated significantly with CD34 positivity of the samples.
DOI:
10.3390/cancers13030581